Lucid Diagnostics (NASDAQ:LUCD) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Lucid Diagnostics (NASDAQ:LUCD) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, signaling a negative outlook from analysts.
• Despite the downgrade, other analysts, such as BTIG Research, have given the stock a "buy" rating with a target price increase from $2.00 to $2.50, indicating mixed sentiment among experts.
• Insider activity has been noted, with Director Dennis Matheis purchasing 100,000 shares at $1.02 each, raising his stake in the company significantly.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Monday.

LUCD has been the topic of a number of other reports. BTIG Research boosted their target price on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the stock a "buy" rating in a report on Friday, September 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Lucid Diagnostics in a report on Saturday, September 27th. Finally, Needham & Company LLC restated a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $3.65.

Lucid Diagnostics Stock Up 2.0%

NASDAQ LUCD opened at $1.04 on Monday. Lucid Diagnostics has a 12-month low of $0.75 and a 12-month high of $1.80. The company has a market capitalization of $138.82 million, a PE ratio of -0.87 and a beta of 1.19. The firm's 50 day moving average is $1.09 and its 200-day moving average is $1.21.

Insider Buying and Selling at Lucid Diagnostics

In other news, Director Dennis Matheis acquired 100,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director directly owned 665,443 shares in the company, valued at $678,751.86. This represents a 17.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.80% of the stock is currently owned by company insiders.

Institutional Trading of Lucid Diagnostics

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in Lucid Diagnostics in the 4th quarter valued at $98,000. XML Financial LLC acquired a new stake in Lucid Diagnostics in the 1st quarter valued at $266,000. Berkshire Asset Management LLC PA acquired a new stake in Lucid Diagnostics in the 1st quarter valued at $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Lucid Diagnostics in the 1st quarter valued at $37,000. Finally, Ghisallo Capital Management LLC acquired a new stake in Lucid Diagnostics in the 1st quarter valued at $629,000. Institutional investors and hedge funds own 74.01% of the company's stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.